Quarterly Results

PERK PHARMACEUTICALS LTD.

NSE : NABSE : 530673ISIN CODE : Industry : Pharmaceuticals & DrugsHouse : Private
BSE1.980 (0 %)
PREV CLOSE ( ) 1.98
OPEN PRICE ( ) 1.98
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 0
TODAY'S LOW / HIGH ( )1.98 1.98
52 WK LOW / HIGH ( ) 00
NSE
This Company is not listed in NSE
Quarters
Select year  
( in Million)
Particulars
Jun 2010
Dec 2009
Sep 2009
Jun 2009
Audited / UnAudited
UnAudited
UnAudited
UnAudited
UnAudited
Net Sales
4.14
3.32
3.09
4.78
Total Expenditure
2.78
3.02
2.82
3.04
PBIDT (Excl OI)
1.36
0.3
0.27
1.74
Other Income
0.00
NA
NA
NA
Operating Profit
1.36
0.3
0.27
1.74
Interest
0.00
NA
NA
NA
Exceptional Items
NA
NA
NA
NA
PBDT
1.36
0.3
0.27
1.74
Depreciation
0.21
0.29
0.29
0.23
Profit Before Tax
1.15
0.01
-0.02
1.51
Tax
0.00
NA
NA
NA
Provisions and contingencies
NA
NA
NA
NA
Profit After Tax
1.15
0.01
-0.02
1.51
Extraordinary Items
NA
NA
NA
NA
Prior Period Expenses
NA
NA
NA
NA
Other Adjustments
NA
NA
NA
NA
Net Profit
1.15
0.01
-0.02
1.51
Equity Capital
63.84
63.84
63.84
63.84
Face Value (IN RS)
10
10
10
10
Reserves
-15.44
-11.24
-11.28
-1.83
Calculated EPS
0.18
0.00
-0.00
0.23
Calculated EPS (Annualised)
0.72
0.00
-0.01
0.94
No of Public Share Holdings
3045200
3045200
3045200
3045200
% of Public Share Holdings
47.7
47.7
47.7
47.7
 
NA
NA
NA
NA
PBIDTM% (Excl OI)
32.85
9.03
8.73
36.40
PBIDTM%
32.85
9.03
8.73
36.40
PBDTM%
32.85
9.03
8.73
36.40
PBTM%
27.77
0.30
-0.64
31.58
PATM%
27.77
0.30
-0.64
31.58
 
Notes
Notes
Notes
Notes

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.